{"disease":{"id":"postmenopausal-women-with-osteoporosis","name":"postmenopausal women with osteoporosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01631214","title":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4093,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05338086","title":"A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":558,"lead_sponsor_name":"mAbxience Research S.L.","has_results":true},{"nct_id":"NCT03974100","title":"Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":527,"lead_sponsor_name":"Sandoz","has_results":true},{"nct_id":"NCT07028320","title":"To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":493,"lead_sponsor_name":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05345691","title":"Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":479,"lead_sponsor_name":"Biocon Biologics UK Ltd","has_results":true},{"nct_id":"NCT04757376","title":"A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":479,"lead_sponsor_name":"Celltrion","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}